Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 977-982

  Cauchi, C ^a   Somaiah, N ^b   Engstrom, P F ^b   Litwin, S ^b   Lopez, M ^a   Lee, J ^b   Davey, M ^b   Bove, B ^b   Von Mehren, M ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

GIST; Kit mutations; Nilotinib; Secondary mutations; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; EXON; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC CORRELATION; GENOTYPE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; LEUKOPENIA; MALE; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOICE CHANGE;

AGED; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES;

EID: 84859805523     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1785-7     Document Type: Article

References (12)

1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480 (Pubitemid 34879334)
2. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620-625 (Pubitemid 351264357)
3. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet 368:1329-1338 (Pubitemid 44528723)
4. Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P (2009) A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 15:5910-5916
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
6. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759 (Pubitemid 46797957)
7. Litwin S, Wong YN, Hudes G (2007) Early stopping design based on progression-free survival at an early time point in the initial cohort. Stat Med 26:4400-4415 (Pubitemid 47534687)
8. Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grünwald V, Roth A, Leyvraz S (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 45:2293-2297
9. Nishida T, Sawaki A, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A (2010) Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. J Clin Oncol 28:15s (suppl; abstr 10015)
10. Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK (2010) Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother Pharmacol 2010 Oct 19 [Epub ahead of print]
11. Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bin Bui N, McArthur GA, Yazji S, Hsu Y, Rutkowski P (2010) Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol 28:15s (suppl; abstr 10017)
12. Heinrich MC, Maki RG, Coreless C, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359